ArticleFrontiers in oncology2025
Human papillomavirus prevalence, genotype distribution, risk factors, and cervical pathology association in women aged 50 years and older: a retrospective cross-sectional study in Xinjiang, China.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent high-risk human papillomavirus (HPV) infection is the primary cause of cervical cancer, but epidemiological data on HPV in women aged ≥50 years-especially in ethnically diverse, resource-limited regions such as Xinjiang, China-remain insufficient. Older women face underrecognized risks due to age-related immune decline and inadequate screening, highlighting the need for targeted research. Methods: A retrospective cross-sectional study was conducted among 640 women aged ≥50 years who underwent cervical HPV testing at a tertiary hospital in Kuqa, Xinjiang, from January 2024 to March 2025. Results: The overall HPV prevalence was 20.6% (132/640), with high-risk genotypes HPV16 (29.5%), HPV53 (18.2%), and HPV58 (12.1%) being the most prevalent. Binary logistic regression showed that a history of cervical surgery (e.g., conization) was strongly associated with a reduced likelihood of HPV positivity (OR=0.015, 95% CI: 0.008--0.028, p<0.001). Univariate analysis indicated that sexual activity frequency was higher in HPV-positive than HPV-negative women (2.35 ± 1.14 vs. 2.11 ± 1.10, t=2.225, p=0.026), but this association was not significant in the multivariate model (OR=1.020, 95% CI: 0.796--1.307, p=0.874). Point-biserial correlation analysis revealed a negative association between HPV positivity and BMI (r_pb=-0.088, p<0.05). HPV-positive women had a higher rate of cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC) compared with HPV-negative women (31.1% vs. 1.2%, p<0.001). A Conclusion: Women aged ≥50 years in Xinjiang have a non-negligible HPV prevalence, with HPV16 and HPV53 as dominant genotypes. A history of cervical surgery was associated with a markedly lower likelihood of HPV detection in this cross-sectional analysis. The association between sexual activity frequency and HPV status was not consistent across analyses and requires cautious interpretation. HPV positivity was strongly correlated with cervical pathological lesions, emphasizing the urgency of tailored screening and prevention strategies for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.